Compare SOPH & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | RZLT |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 471.0M |
| IPO Year | 2021 | 2011 |
| Metric | SOPH | RZLT |
|---|---|---|
| Price | $7.07 | $3.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $9.75 | ★ $9.80 |
| AVG Volume (30 Days) | 524.7K | ★ 1.5M |
| Earning Date | 11-03-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.25 | N/A |
| Revenue Next Year | $24.62 | $2,214.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.83 | $1.07 |
| 52 Week High | $8.98 | $11.46 |
| Indicator | SOPH | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 43.44 |
| Support Level | $4.58 | $3.58 |
| Resistance Level | $8.80 | $4.09 |
| Average True Range (ATR) | 0.47 | 0.30 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 44.75 | 36.47 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.